SBBP Strongbridge Biopharma plc

4.00
0  -7%
Previous Close 4.30
Open 4.25
Price To book 1.51
Market Cap 84.82M
Shares 21,205,000
Volume 40,749
Short Ratio 0.90
Av. Daily Volume 126,612

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment from second trial to begin mid-2017 with top-line data expected in 3Q 2018.
COR-003 (levoketoconazole) - LOGICS
Endogenous Cushing’s syndrome
Phase 3 top-line data due 1Q 2018.
COR-003 (levoketoconazole) - SONICS
Endogenous Cushing’s syndrome

Latest News

  1. Strongbridge Biopharma plc Announces New Employment Inducement Awards
  2. Strongbridge Biopharma plc to Present at the 27th Annual Oppenheimer Healthcare Conference and the 16th Annual Needham Healthcare Conference
  3. Can The Uptrend Continue for Strongbridge Biopharma (SBBP)?
  4. Strongbridge Biopharma plc to Present at the 37th Annual Cowen and Company Healthcare Conference and the 29th Annual ROTH Conference
  5. Strongbridge Biopharma plc Announces Annual General Meeting of Shareholders
  6. Strongbridge Biopharma plc to Participate in the Canaccord Genuity Rare Disease and BioPharma One-on-One Day
  7. Strongbridge Biopharma plc Expands Commercial Capabilities with Two Rare Disease Executive Hires
  8. Strongbridge Biopharma plc Announces Closing of $35 Million Equity Financing and $40 Million Credit Facility
  9. Post Earnings Coverage as Strongbridge Loss Narrowed; Acquires US Rights for KEYEVIS and Announced Equity Financing
  10. Strongbridge Biopharma plc to Present at Biotech Showcase 2017
  11. Strongbridge Biopharma plc to Present at Biotech Showcase 2017
  12. $35M infusion: Bucks County biopharm firm reaches funding deal
  13. Strongbridge Biopharma plc Announces Closing of $35 Million Equity Financing and $40 Million Credit Facility
  14. Strongbridge Biopharma plc Announces Closing of $35 Million Equity Financing and $40 Million Credit Facility
  15. Stonebridge Biopharma raises $35 million by selling shares at a deep discount
  16. Strongbridge Biopharma plc Announces $35 Million Equity Financing
  17. Strongbridge Biopharma plc Announces Acquisition of U.S. Rights to KEVEYIS® From Taro
  18. Strongbridge Biopharma plc Provides Corporate and Financial Update
  19. Strongbridge Biopharma plc Provides Corporate and Financial Update
  20. Strongbridge Biopharma plc Announces Acquisition of U.S. Rights to KEVEYIS® From Taro